Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy

Oncotarget

Volumn 7, Issue 39, 2016, Pages 63829-63838

  Valdez, Benigno C ^a   Li, Yang ^a   Murray, David ^b   Brammer, Jonathan E ^a   Liu, Yan ^a   Hosing, Chitra ^a   Nieto, Yago ^a   Champlin, Richard E ^a   Andersson, Borje S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Combination therapy; Drug transporter; HDAC inhibitors; Lymphoma; Pre transplant regimen

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BELINOSTAT; BUSULFAN; CHLORAMBUCIL; DAUNORUBICIN; DNA; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; NUCLEOSIDE ANALOG; PANOBINOSTAT; ROMIDEPSIN; VORINOSTAT; ABC TRANSPORTER SUBFAMILY B; ABCB1 PROTEIN, HUMAN; DEPSIPEPTIDE; HYDROXAMIC ACID; INDOLE DERIVATIVE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; SULFONAMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG POTENTIATION; EPIGENETICS; HUMAN; HUMAN CELL; LYMPHOMA; MITOCHONDRIAL MEMBRANE; MONONUCLEAR CELL; PROTEIN EXPRESSION; T CELL LYMPHOMA; APOPTOSIS; CELL DEATH; CELL PROLIFERATION; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DEPSIPEPTIDES; DNA METHYLATION; DRUG SYNERGISM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LYMPHOMA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA, MESSENGER; SULFONAMIDES; UP-REGULATION;

EID: 84993949220     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11561     Document Type: Article

References (30)

1. Andersson BS, Valdez BC, Jones R. Pharmacologic basis for high-dose chemotherapy. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR (Eds). Thomas' Hematopoietic Cell Transplantation, 5th edn. Wiley-Blackwell, Oxford, UK, 2016. pp 211-222.
2. Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol. 2011; 81:222-32.
3. Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012; 40:800-10.
4. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N et al. Vorinostat combined with high-dose gemcitabine, busulfan, and melphalan with autologous stem cell transplantation in patients with refractory lymphomas. Biol Blood Marrow Transplant. 2015; 21:1914-20.
5. Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma. 2016. In press.
6. Köck K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA, Kroemer HK. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet. 2007; 46:449-70.
7. Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci. 2006; 27:438-46.
8. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 2006; 86:849-99.
9. Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007; 59:752-7.
10. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res. 2006; 12:1547-55.
11. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009; 280:192-200.
12. Dogan AL, Legrand O, Faussat AM, Perrot JY, Marie JP. Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines. Leuk Res. 2004; 28:619-22.
13. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun. 1995; 208:345-52.
14. Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry. 2002; 48:59-65.
15. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008; 9:105-27.
16. Hobbs AS, Froehlich JP, Albers RW. Inhibition by vanadate of the reactions catalyzed by the (Na+ + K+)-stimulated ATPase. A transient state kinetic characterization. J Biol Chem. 1980; 255:5724-7.
17. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem. 1992; 267:4854-8.
18. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei A, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, et al. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016. In press.
19. Paumi CM, Ledford BG, Smitherman PK, Townsend AJ, Morrow CS. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J Biol Chem. 2001; 276:7952-6.
20. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 2002; 3:224-9.
21. Miller JL, Grant PA. The role of DNA methylation and histone modifications in transcriptional regulation in humans. Subcell Biochem. 2013; 61:289-317.
22. Vaute O, Nicolas E, Vandel L, Trouche D. Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res. 2002; 30:475-81.
23. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129:823-37.
24. Koch CM, Andrews RM, Flicek P, Dillon SC, Karaöz U, Clelland GK, Wilcox S, Beare DM, Fowler JC, Couttet P, James KD, Lefebvre GC, Bruce AW et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res. 2007; 17:691-707.
25. Rosenfeld JA, Wang Z, Schones DE, Zhao K, DeSalle R, Zhang MQ. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genomics. 2009; 10:143.
26. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003; 8:411-24.
27. Ravid Z, Goldblum N, Zaizov R, Schlesinger M, Kertes T, Minowada J, Verbi W, Greaves M. Establishment and characterization of a new leukaemic T-cell line (Peer) with an unusual phenotype. Int J Cancer. 1980; 25:705-10.
28. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976; 17:565-77.
29. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfanresistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010; 34:364-72.
30. Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Exp Hematol. 2015; 43:448-61.